Baker Bros. Advisors LP Stoke Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $12.3 Billion
- Q3 2025
A detailed history of Baker Bros. Advisors LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 4,633,838 shares of STOK stock, worth $123 Million. This represents 0.89% of its overall portfolio holdings.
Number of Shares
4,633,838
Previous 4,633,838
-0.0%
Holding current value
$123 Million
Previous $52.6 Million
107.05%
% of portfolio
0.89%
Previous 0.53%
Shares
9 transactions
Others Institutions Holding STOK
# of Institutions
160Shares Held
60.2MCall Options Held
563KPut Options Held
101K-
Black Rock Inc. New York, NY5.41MShares$143 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$143 Million24.66% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$136 Million1.61% of portfolio
-
Redmile Group, LLC San Francisco, CA4.18MShares$111 Million10.81% of portfolio
-
Morgan Stanley New York, NY3.54MShares$93.8 Million0.01% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.05B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...